Spironolactone and Caffeine Interaction: What Acne Patients Need to Know
At a glance
- Label status / Caffeine is not named in the Aldactone drug interactions section
- Metabolism / No shared metabolic step is documented; caffeine is cleared mainly by CYP1A2
- Potassium / Label asks for a serum potassium check within 1 week of starting or titrating
- Hydration / Label warns of symptomatic dehydration, hypotension and worsening renal function from excessive diuresis
- Acne status / Off-label; labeled uses are heart failure, add-on hypertension, edema and hyperaldosteronism
- Acne dose studied / 50 mg daily to week 6, then 100 mg daily to week 24 in the SAFA trial
- FDA caffeine reference / 400 mg a day, about two to three 12-fl-oz cups of coffee
- Estrogen effect / Combined oral contraceptives slow caffeine clearance
Is caffeine a listed spironolactone interaction?
No. The Aldactone label's drug interactions section names agents that raise serum potassium (ACE inhibitors, angiotensin receptor blockers, NSAIDs, heparin and low molecular weight heparin, trimethoprim), plus lithium, digoxin, cholestyramine, acetylsalicylic acid, abiraterone and mitotane [1]. Caffeine does not appear in it, and the label sets no caffeine limit [1].
That is what the label says, not a test result.
Do caffeine and spironolactone share a metabolic pathway?
No documented one. Spironolactone is rapidly and extensively metabolized, and the label names no cytochrome P450 enzyme at any step. It divides the metabolites into those where the sulfur is removed (canrenone) and those where it is retained (7-alpha-thiomethylspironolactone, or TMS, and 6-beta-hydroxy-7-alpha-thiomethylspironolactone, or HTMS) [1]. Spironolactone peaks at 2.6 hours with a mean half-life of 1.4 hours; canrenone peaks at 4.3 hours with a half-life of 16.5 hours [1].
Caffeine works the other way round: one enzyme carries most of the load. CYP1A2 catalyses the 3-N-demethylation that is the main human route, and the FDA lists caffeine as a clinical index substrate for CYP1A2 [3][4]. Reported mean caffeine half-lives in healthy non-smokers run from about 3.4 hours to about 6.2 hours [5][6].
What the label says to watch for
Potassium first. The label states that spironolactone can cause hyperkalemia, that the risk rises with impaired renal function, potassium supplements, potassium-containing salt substitutes and potassium-raising drugs such as ACE inhibitors and ARBs, and that serum potassium should be checked within 1 week of starting or titrating and regularly after that, more often in those situations. If hyperkalemia occurs, the label directs lowering the dose or stopping and treating it [1].
Blood pressure and kidneys next. The label warns that excessive diuresis may cause symptomatic dehydration, hypotension and worsening renal function, particularly in salt-depleted patients or those taking ACE inhibitors or ARBs, and that aminoglycosides, cisplatin and NSAIDs add renal risk [1]. It also lists hyponatremia, hypomagnesemia, hypocalcemia, hypochloremic alkalosis and hyperglycemia among possible metabolic abnormalities [1].
How often this shows up in acne patients: a retrospective study of 974 healthy young women taking spironolactone for acne found 13 abnormal potassium values in 1802 measurements (0.72%), against a 0.76% baseline rate in 1165 comparison women, and 6 of the 13 repeated normal. The authors concluded that routine potassium monitoring has low usefulness in this group, which excluded women with heart or kidney disease and those taking drugs that act on the renin-angiotensin system [7]. The label still asks for monitoring [1].
Does coffee add to spironolactone's fluid loss?
In people who drink coffee regularly, the studies found little diuretic effect. A review of caffeine and fluid balance found that large single doses (at least 250 to 300 mg) increase short-term urine output in people who have avoided caffeine for days or weeks, that tolerance to this effect develops with regular use, and that the caffeine in standard servings of tea, coffee and soft drinks appears to have no diuretic action [8].
A crossover study points the same way. Fifty men who habitually drank 3 to 6 cups of coffee a day took either 4 x 200 mL of coffee at 4 mg/kg caffeine or the same volume of water for three days each. Twenty-four-hour urine volume was 2409 +/- 660 mL with coffee and 2428 +/- 669 mL with water, with no differences in total body water, blood markers, urine specific gravity, osmolality or creatinine; urinary sodium excretion was higher with coffee [9]. Those were men who already drank coffee, not women taking spironolactone, so the study describes coffee rather than the combination.
How much caffeine is 400 mg?
The FDA cites 400 mg a day, about two to three 12-fluid-ounce cups of coffee, as an amount not generally associated with negative effects in most adults, while noting wide variation in sensitivity and in how fast people clear caffeine, and that some conditions and medications raise sensitivity [2]. Its per-12-fl-oz figures: regular brewed coffee 113 to 247 mg, energy drink 41 to 246 mg, black tea 71 mg, green tea 37 mg, caffeinated soft drink 23 to 83 mg. Energy drinks generally run 54 to 328 mg per 16 fl oz [2]. Decaf is not caffeine-free: typically 2 to 15 mg per 8-fl-oz cup [2].
Estrogen-containing contraceptives and caffeine
In a series of 403 women treated with spironolactone for acne, menstrual side effects were less common among those using combined oral contraception (odds ratio 0.23, 95% CI 0.11 to 0.50) [10]. Estrogen-containing pills have a measured effect on caffeine handling:
- In 1985, women who had used low-dose estrogen pills for more than 3 months took 162 mg of caffeine: half-life 7.88 hours versus 5.37 hours in 9 matched controls, clearance 1.05 versus 1.75 mL/min/kg [11].
- In 1980, 9 pill users and 9 non-users took 250 mg of caffeine: half-life 10.7 +/- 3.0 versus 6.2 +/- 1.6 hours, clearance 0.79 versus 1.3 mL/min/kg [6].
- In 1999, 12 postmenopausal women took oral estradiol for 8 weeks; their caffeine metabolic ratio (paraxanthine to caffeine) fell by a mean of 29.2 +/- 25.0, p = 0.0019, which the authors read as inhibition of CYP1A2-mediated caffeine metabolism [12].
Menstrual cycle effects are smaller: clearance was slower in the late luteal phase in 10 women, with no change in half-life, and the authors thought the effect too small to matter for most women [13].
What these studies measured was caffeine clearance and half-life. They did not measure jitteriness, sleep or acne.
Is acne a labeled use, and what dose was studied?
Acne is not a labeled use. The Aldactone label covers heart failure, add-on hypertension, edema and primary hyperaldosteronism, with doses from 25 mg once daily in heart failure to 100 to 400 mg daily in primary hyperaldosteronism [1]. For acne the drug is used off-label, and the best randomized evidence used 50 mg a day for 6 weeks, then 100 mg a day to week 24: in 410 women, the acne-specific quality-of-life symptom score favored spironolactone by 1.27 points at 12 weeks and 3.77 points at 24 weeks, and investigator-rated success at week 12 was 18.5% versus 5.6% (adjusted odds ratio 5.18, 95% CI 2.18 to 12.28) [14].
Bottom line
Caffeine is not a listed spironolactone interaction in the Aldactone label, and the label's monitoring concerns are potassium, blood pressure and hydration rather than anything caffeine-specific [1]. The FDA figure of 400 mg a day is a general adult reference, not a spironolactone-specific limit [2]. In studies, combined estrogen-containing contraceptives slowed caffeine clearance [11][6].
Frequently asked questions
Can I drink coffee while taking spironolactone?
Does caffeine make spironolactone less effective for acne?
Does spironolactone change how long caffeine lasts?
What potassium monitoring does the label call for?
How much caffeine is in coffee and energy drinks?
Do birth control pills change caffeine while I am on spironolactone?
References
- U.S. National Library of Medicine, DailyMed. Aldactone (spironolactone) tablets, Pfizer prescribing information. Aldactone (spironolactone) tablets, Pfizer label
- Spilling the Beans: How Much Caffeine is Too Much? | FDA. Spilling the Beans: How Much Caffeine is Too Much? | FDA
- Kot M, Daniel WA. Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacol Rep. 2008;60(6):789-97. Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat
- Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers | FDA. Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers | FDA
- Knutti R, Rothweiler H, Schlatter C. Effect of pregnancy on the pharmacokinetics of caffeine. Eur J Clin Pharmacol. 1981;21(2):121-6. Effect of pregnancy on the pharmacokinetics of caffeine
- Patwardhan RV, Desmond PV, Johnson RF, Schenker S. Impaired elimination of caffeine by oral contraceptive steroids. J Lab Clin Med. 1980;95(4):603-8. Impaired elimination of caffeine by oral contraceptive steroids
- Plovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA Dermatol. 2015;151(9):941-4. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne
- Maughan RJ, Griffin J. Caffeine ingestion and fluid balance: a review. J Hum Nutr Diet. 2003;16(6):411-20. Caffeine ingestion and fluid balance: a review
- Killer SC, Blannin AK, Jeukendrup AE. No evidence of dehydration with moderate daily coffee intake: a counterbalanced cross-over study in a free-living population. PLoS One. 2014;9(1):e84154. No evidence of dehydration with moderate daily coffee intake: a counterbalanced cross-over study in a free-living population
- Garg V, Choi JK, James WD, Barbieri JS. Long-term use of spironolactone for acne in women: A case series of 403 patients. J Am Acad Dermatol. 2021;84(5):1348-1355. Long-term use of spironolactone for acne in women: A case series of 403 patients
- Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol. 1985;28(4):425-8. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives
- Pollock BG, Wylie M, Stack JA, Sorisio DA, Thompson DS, Kirshner MA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol. 1999;39(9):936-40. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women
- Lane JD, Steege JF, Rupp SL, Kuhn CM. Menstrual cycle effects on caffeine elimination in the human female. Eur J Clin Pharmacol. 1992;43(5):543-6. Menstrual cycle effects on caffeine elimination in the human female
- Santer M, Lawrence M, Pyne S, Renz S, Stuart BL, Sach T, et al. Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT. Health Technol Assess. 2024;28(56):1-86. Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT